|Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 515 active entries
Phone: +30 6945673841
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Synpromics Ltd is a Biotech company incorporated with a view to develop a series of synthetic promoters that can be used to control genes under a variety of settings. It is envisaged that the products produced by Synpromics will be applied in life science R&D, the conception of novel diagnostic approaches and in the development of gene therapeutics.
“It is our mission to be a global leader in synthetic biology; specifically we hope to set the standard in the development of man-made gene regulators and to apply these novel tools in the generation of a new class of diagnostics and therapies.”
It is our philosophy to provide custom-made products to our clients. By doing this we can immediately meet their needs, supplying a product exactly tailored to each specific application. We further aim to build a range of conditional and tissue-specific promoters that can be widely used by the research community. Ultimately, it is envisaged that Synpromics will be the market leader in the supply of synthetic regulatory systems applicable across a wide range of systems.
Synpromics has been incorporated with unique access to proprietary technology aimed at constructing gene control elements specifically active under a plethora of conditions. It is the shear breadth of the application of this technology makes Synpromics so competitive. The technology is broadly applicable over the biotech arena and as such we anticipate numerous opportunities to partner with large pharmaceutical companies. Synpromics also recognises the importance of establishing an effective R&D program in order to improve on its platform and to conceive of new technologies to bring the company forward. It is for this reason that significant effort has been placed in the development of a highly-motivated team dedicated to achieving the full potential of Synpromics.
Founder and Chairman
One of the major strengths of Synpromics is the experience brought into the company by Dr Michael L. Roberts; its founder and Managing Director. Dr Roberts read Biochemistry at the University of Glasgow, where he achieved a first class honours degree. He subsequently studied for his doctorate at the University of Cambridge where his interest in the elements controlling gene expression was stimulated. After post-doctoral work at Royal Holloway, University of London, in one of the leading gene therapy groups in Europe and a two-year Marie Curie fellowship in the National Hellenic Research Foundation in Greece, Dr Roberts was appointed head of Research and Development at Regulon Inc, where he was later appointed to the board of directors. Upon leaving Regulon Dr Roberts iimmediately worked on the incorporation of Synpromics Ltd in order to commercially exploit a number of his own inventions.
Last update of this entry: July 11, 2012